Dosage and administration
Put 1 to 2 drops in the affected eye(s) up to 4 times daily children under 6 years of age: ask a doctor
Put 1 to 2 drops in the affected eye(s) up to 4 times daily children under 6 years of age: ask a doctor
store between 15° to 25°C (59°F to 77°F)
Glycerin 0.2%
Hypromellose 0.2%
Polyethylene Glycol 400 1%
Lubricant
Lubricant
Lubricant
ask a health professional before use.
If swallowed, get medical help or contact a Poison Control Center right away.
store between 15° to 25°C (59°F to 77°F)
Ascorbic acid, benzalkonium chloride, boric acid, dextrose, magnesium chloride, potassium chloride, purified water, sodium borate, sodium chloride, sodium citrate, sodium lactate
Pureaid Artificial Tears
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 259581 | glycerin 0.2 % / hypromellose 0.2 % / polyethylene glycol 400 1 % Ophthalmic Solution | PSN | 3 |
| 259581 | glycerin 2 MG/ML / hypromellose 2 MG/ML / polyethylene glycol 400 10 MG/ML Ophthalmic Solution | SCD | 3 |
| 259581 | glycerin 0.2 % / hypromellose 0.2 % / PEG 400 1 % Ophthalmic Solution | SY | 3 |
| Class | Version | Type | Effective |
|---|---|---|---|
| GLYCERIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 67510-0063-5 | 2022-01-28 | C162847 | 48780-1 | d6a99b39-50d7-a426-e053-dadaa90af4c2 | Pure-Aid Artificial Tears |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67510-0063-5 | Tears Lubricant | 15 mL in 1 BOTTLE | LIQUID | 15 | 3 | |
| 67510-0063-5 | Tears Lubricant | 1 in 1 BOX | LIQUID | 1 | 3 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 67510-0063 | TEARS LUBRICANT (GLYCERIN, HYPROMELLOSES, POLYETHYLENE GLYCOL 400) LIQUID [KAREWAY PRODUCT, INC.] | 3 | Legacy NDC, 2 package rows | 20191029_d98abe91-1967-4a07-9730-e98766912d68.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| GLYCERIN | ACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| HYPROMELLOSES | ACTIVE INGREDIENT | 3NXW29V3WO | 1 | |
| POLYETHYLENE GLYCOL 400 | ACTIVE INGREDIENT | B697894SGQ | 1 | |
| GLYCERIN | ACTIVE MOIETY | PDC6A3C0OX | 1 | |
| HYPROMELLOSES | ACTIVE MOIETY | 3NXW29V3WO | 1 | |
| POLYETHYLENE GLYCOL 400 | ACTIVE MOIETY | B697894SGQ | 1 | |
| ASCORBIC ACID | INACTIVE INGREDIENT | PQ6CK8PD0R | 1 | |
| BENZALKONIUM CHLORIDE | INACTIVE INGREDIENT | F5UM2KM3W7 | 1 | |
| BORIC ACID | INACTIVE INGREDIENT | R57ZHV85D4 | 1 | |
| DEXTROSE | INACTIVE INGREDIENT | IY9XDZ35W2 | 1 | |
| MAGNESIUM CHLORIDE | INACTIVE INGREDIENT | 02F3473H9O | 1 | |
| POTASSIUM CHLORIDE | INACTIVE INGREDIENT | 660YQ98I10 | 1 | |
| SODIUM BORATE | INACTIVE INGREDIENT | 91MBZ8H3QO | 1 | |
| SODIUM CITRATE | INACTIVE INGREDIENT | 1Q73Q2JULR | 1 | |
| SODIUM LACTATE | INACTIVE INGREDIENT | TU7HW0W0QT | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 67510-0063 | 67510-0063-5 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| BORIC ACID | R57ZHV85D4 | IACT |
| ASCORBIC ACID | PQ6CK8PD0R | IACT |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
| DEXTROSE | IY9XDZ35W2 | IACT |
| MAGNESIUM CHLORIDE | 02F3473H9O | IACT |
| POTASSIUM CHLORIDE | 660YQ98I10 | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM BORATE | 91MBZ8H3QO | IACT |
| SODIUM CITRATE | 1Q73Q2JULR | IACT |
| SODIUM LACTATE | TU7HW0W0QT | IACT |
| GLYCERIN | PDC6A3C0OX | ACTIB |
| HYPROMELLOSES | 3NXW29V3WO | ACTIB |
| POLYETHYLENE GLYCOL 400 | B697894SGQ | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | SUSPENSION/ DROPS / OPHTHALMIC | 0.03 %w/w | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | CAPSULE, DELAYED RELEASE / ORAL | 12 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SHAMPOO / TOPICAL | 0.2 %w/w | ||
| MAGNESIUM CHLORIDE | MAGNESIUM CHLORIDE | 02F3473H9O | INJECTION, SOLUTION / INTRATHECAL | 1 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1440 mg | ||
| MAGNESIUM CHLORIDE | MAGNESIUM CHLORIDE | 02F3473H9O | SOLUTION/ DROPS / OPHTHALMIC | 0.03 %w/v | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 0.53 %w/v | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | TABLET / SUBLINGUAL | 115.78 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION, SOLUTION / INTRATHECAL | 1 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SOLUTION / RESPIRATORY (INHALATION) | 0.04 %w/w | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | GEL / OPHTHALMIC | 0.5 %w/w | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | SYRUP / ORAL | 620 mg | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 2 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION/ DROPS / OPHTHALMIC | 0.14 %w/v | ||
| MAGNESIUM CHLORIDE | MAGNESIUM CHLORIDE | 02F3473H9O | SOLUTION / OPHTHALMIC | 0.01 %w/v | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION / INTRAOCULAR | 38 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SUSPENSION / OPHTHALMIC | 0.03 %w/w | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | POWDER, FOR SOLUTION / ORAL | 560 mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | INJECTION, SOLUTION / INTRAVENOUS | 210 mg | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | SOLUTION/ DROPS / OPHTHALMIC | 1.1 %w/v | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION / INTRAVENOUS | 1440 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / OPHTHALMIC | 1 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | SOLUTION / ORAL | 2489 mg/5ml | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY / NASAL | 1 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | INJECTION, SOLUTION / INTRATHECAL | 1925 mg | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | CREAM / TOPICAL | NA | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / TOPICAL | NA | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | EMULSION / OPHTHALMIC | 0.11 %w/v | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | MOUTHWASH / BUCCAL | 7.36 mg/1ml | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRAMUSCULAR | 1 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION / INTRAVENOUS | 1 mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SUSPENSION/ DROPS / AURICULAR (OTIC) | 3 mg | ||
| SODIUM LACTATE | SODIUM LACTATE | TU7HW0W0QT | GEL / TOPICAL | 4 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | PASTILLE / ORAL | 826 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / AURICULAR (OTIC) | 0 %w/v | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SUSPENSION/ DROPS / TOPICAL | 0.3 %w/v | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | SOLUTION / AURICULAR (OTIC) | 0.3 %w/w | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | AEROSOL, METERED / RESPIRATORY (INHALATION) | 0.1 %w/w | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | LOZENGE / BUCCAL | NA | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SOLUTION/ DROPS / OPHTHALMIC | 48 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION / INFILTRATION | 0.3 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | CAPSULE / ORAL | 62 mg | ||
| SODIUM LACTATE | SODIUM LACTATE | TU7HW0W0QT | SUSPENSION / ORAL | 20 mg/1ml | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | POWDER / NASAL | NA | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | GEL / OPHTHALMIC | 0.01 %w/w | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | INJECTION / INTRASPINAL | 75 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION / AURICULAR (OTIC) | 0.01 %w/v | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | TABLET, COATED / ORAL | 132 mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SOLUTION / AURICULAR (OTIC) | 0.05 %w/w | ||
| MAGNESIUM CHLORIDE | MAGNESIUM CHLORIDE | 02F3473H9O | SOLUTION / INTRAOCULAR | 15 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | LIQUID / NASAL | 0.2 mg/1ml | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SOLUTION / TOPICAL | 0.04 %w/w | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | CAPSULE, DELAYED RELEASE / ORAL | 2 mg | ||
| SODIUM LACTATE | SODIUM LACTATE | TU7HW0W0QT | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 18.7 mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 0.3 %w/w | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / OPHTHALMIC | 2 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRALESIONAL | 1 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / TOPICAL | 0.02 %w/v | ||
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | INJECTION, SOLUTION / INFILTRATION | 0.2 %w/v | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | EMULSION / OPHTHALMIC | 0.3 %w/v |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 96033323-9233-6160-e053-2995a90aa97d | d98abe91-1967-4a07-9730-e98766912d68 | 2019-10-28 | Warnings | 96033323-9233-6160-e053-2995a90aa97d d98abe91-1967-4a07-9730-e98766912d68 |
Adverse event summaries are temporarily unavailable. Other product information remains available.